Sign up Australia
Proactive Investors - Run By Investors For Investors

Small-Cap Snapshot: ADMA Biologics shares rise after FDA accepts its drug application amendment

The biotech acquired the drug Bivigam in an acquisition but production stopped while the facility was renovated
Scientist in a lab
Bivigam is a treatment for immune system disorders

Supervalu Inc (NYSE:SVU) is a top gainer following a US$2.9bn buyout deal from United Natural Foods Inc (NASDAQ:UNFI). The grocery retailer is the primary supplier of Amazon.com Inc’s Whole Foods. Shareholders will receive US$32.50 per share in cash. Shares of the Minnesota-based company were up nearly 65% to US$32.02 in Thursday morning trading.

ADMA Biologics Inc (NASDAQ:ADMA) shares are up following the announcement that the US Food and Drug Administration accepted its amendment to its drug application. The biotech acquired the drug Bivigam, a treatment for immune disorders, in an acquisition. Production stopped while the facility was shut down and renovated. Shares of the New Jersey-based company were up more than 18% to US$5.86.

Genprex Inc (NASDAQ:GNPX) inked a deal with the University of Texas MD Anderson Cancer Center. The pair will work together on a study of its drug Oncoprex, administering it alongside immunotherapies. The clinical-stage gene therapy company will pay the university center US$2mln to conduct the study. Shares of the company were down around 1.5% to US$6.99.

READ: Small-Cap Snapshot: Medical device company Nevro is on the rise after a court rules in its favor

MoSys Inc (NASDAQ:MOSY) was a top decliner after announcing it would soon lose a major customer. The semiconductor company reported earnings of US$0.06 per share compared with an earnings loss of US$0.42 in its previous second quarter. However, news that an unnamed customer would be phasing out its products in the next 24 months offset the positive results. Shares fell more than 40% to US$1.21.

LSB Industries Inc (NYSE:LXU) shares sank as downtime at the chemical maker’s factories weighed on its second-quarter results. The company reported a net loss of US$27.5mln compared with a loss of US$7mln in its previous second quarter. Its El Dorado ammonia facility in Arkansas was out of service after a power outage caused tube failures. Shares of the Oklahoma-based company were down more than 15% to US$6.53.

The Russell 2000 small-cap index was up slightly in Thursday afternoon trading.

View full MOSY profile View Profile

MoSys Timeline

Related Articles

Enertopia Corp's partner GWT upbeat on potential of lithium recovery tests
October 26 2017
The feedstock used in the tests comes from the group's Clayton valley project in Nevada
Picture of facilities at Bauxite Hills
May 11 2018
The project is forecast to generate earnings before interest, tax, depreciation and amortisation (EBITDA) of $2.5 billion.
chrome pipes
June 20 2018
Another change recently was for Tharisa to take over the running of the mine, which involved it buying the fleet from its contractor

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use